Using contrast-enhanced digital mammography (CEDM) to evaluate low to moderately suspicious breast lesions can greatly reduce biopsies in patients with benign lesions, according to a study published Sept. 5 in Academic Radiology.

Patients with a family or personal history of allergic reactions to contrast media are in danger of experiencing future reactions, according to a study published Sept. 3 in Radiology.  

The new agent is manganese-based (Mn-PyC3A) and produces tumor contrast enhancement similarly to that seen when using “state of the art” gadolinium-based contrast agents (GBCAs).

A skin test may help clinicians prevent adverse drug reactions in patients receiving radiocontrast material, according to a new study published in the American Journal of Roentgenology.

A new study found that chronic kidney disease patients who received IV contrast-enhanced imaging faced no more risk of developing contrast-induced nephropathy than those who did not receive contrast material.

The FDA has approved Bayer’s gadobutrol (Gadavist) injection for use in cardiac MRI, making it the first contrast agent approved for the imaging technique, according to a statement from Bayer.

Contrast-enhanced spectral mammography (CESM) can be a helpful method to screen for postoperative breast cancer when paired with traditional mammography, according to research published July 6 in Clinical Radiology.

Dynamic contrast-enhanced (DCE) MRI can help measure the permeability of the blood-brain barrier (BBB) in areas of the brain associated with migraines, potentially providing insight into the debilitating headaches and other neurovascular disorders.